Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future.

2,488 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Intratumor heterogeneity: the Rosetta stone of therapy resistance (2020, background): “Genetic heterogeneity is the most studied and best understood aspect of intratumor heterogeneity (ITH), although our understanding is still far from being sufficiently complete (McGranahan and Swanton, 2017).”
Mitochondrial metabolism and cancer (2017, background): “Progressing malignancies acquire a high degree of phenotypic and metabolic plasticity as they establish functional interactions with non-transformed components of the tumor microenvironment [114-116].”
Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer (2019, background): “It should be noted that the conclusion of the current study is mainly is related to transcriptomic heterogeneity, while ITH is often discussed in the context of cancer genomic diversity linked to tumor evolution (Burrell et al., 2013; Gerlinger et al., 2012; McGranahan and Swanton, 2017).”
Dynamic EMT: a multi‐tool for tumor progression (2021, neutral): “Notably, tumors display not only spatial but also temporal heterogeneity within the same individual that can be elicited, e.g., via the occurrence of consecutive mutations and clonal evolution (McGranahan & Swanton, 2017).”
Precision Oncology: The Road Ahead (2017, background): “These have been promising strategies to exploit genome instability - as one driving force of heterogeneity -- therapeutically [25].”